XTRA:EVTLife Sciences
Evotec (XTRA:EVT) Turns Q4 Profit Challenging Longstanding Loss Narrative
Evotec (XTRA:EVT) has closed FY 2025 with fourth quarter revenue of €253.3 million and basic EPS of €0.08, alongside trailing twelve month revenue of €788.4 million and a net loss of €103.5 million. Over recent quarters the company has seen quarterly revenue range from €163.9 million to €253.3 million, with basic EPS moving from a loss of €0.24 in Q3 2025 to a profit of €0.08 in Q4 2025. This sets up a mixed picture for margins as investors weigh short term profitability against a still loss...